Free fatty acid 3 receptor agonist AR420626 reduces allergic responses in asthma and eczema in mice

Ye Ji Lee, So Eun Son, Dong Soon Im

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Free fatty acid 3 receptor (FFA3; previously GPR41) is a G protein-coupled receptor that senses short-chain fatty acids and dietary metabolites produced by the gut microbiota. FFA3 deficiency reportedly exacerbates inflammatory events in asthma. Herein, we aimed to determine the therapeutic potential of FFA3 agonists in treating inflammatory diseases. We investigated the effects of N-(2,5-dichlorophenyl)-4-(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide (AR420626), an FFA3 agonist, in in vivo models of chemically induced allergic asthma and eczema in BALB/c mice. Administration of AR420626 decreased the number of immune cells in the bronchoalveolar lavage fluid and skin. AR420626 suppressed inflammatory cytokine expression in the lung and skin tissues. Histological examination revealed that AR420626 suppressed inflammation in the lungs and skin. Treatment with AR420626 significantly suppressed the enhanced lymph node size and inflammatory cytokine levels. Overall, FFA3 agonist AR420626 could suppress allergic asthma and eczema, implying that activation of FFA3 might be a therapeutic target for allergic diseases.

Original languageEnglish
Article number111428
JournalInternational Immunopharmacology
Volume127
DOIs
Publication statusPublished - 25 Jan 2024

Bibliographical note

Publisher Copyright:
© 2023 Elsevier B.V.

Keywords

  • Anti-allergic
  • Anti-asthmatic
  • Anti-eczema
  • FFA3
  • Free fatty acid receptor 3
  • Short-chain fatty acids

Fingerprint

Dive into the research topics of 'Free fatty acid 3 receptor agonist AR420626 reduces allergic responses in asthma and eczema in mice'. Together they form a unique fingerprint.

Cite this